Role of IL-6 and IL-6 targeted therapy in systemic lupus erythematosus. Rheumatology (Oxford) 2023 Dec 01;62(12):3804-3810
Date
08/18/2023Pubmed ID
37594751DOI
10.1093/rheumatology/kead416Scopus ID
2-s2.0-85178359347 (requires institutional sign-in at Scopus site) 3 CitationsAbstract
Interleukin-6 (IL-6) is one of the cytokines implicated in murine and human SLE. Only a few small studies have investigated IL-6 inhibition in human SLE. Currently, there are no studies registered in clinicaltrials.gov to assess the IL-6 targeted therapy in SLE, yet its role in the future remains to be defined. This narrative review analyses these and potential areas of future studies with IL-6 targeted therapy in SLE.
Author List
Nepal D, Gazeley DAuthor
David J. Gazeley MD Associate Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsCytokines
Humans
Interleukin-6
Lupus Erythematosus, Systemic
Mice
Severity of Illness Index